Tafluprost-d4

Formulation: A solution in methyl acetate

Formal Name: (5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxy-1-buten-1-yl]-3,5-dihydroxycyclopentyl]-5-heptenoic acid-d4, 1-methylethyl ester

Purity: ≥99% deuterated forms (d1-d4)

Formula Markup: C25H30D4F2O5

Formula Weight: 456,6

Shelf life (days): 730

Notes: Tafluprost-d4 is intended for use as an internal standard for the quantification of tafluprost (Item No. 10005440) by GC- or LC-MS. Tafluprost is a prodrug form of the FP receptor agonist tafluprost (free acid) (Item No. 10005439) and a derivative of the prostaglandin F2α (PGF2α; Item Nos. 16010 / 16020).{11598} It decreases pupillary diameter in cats when applied topically at doses of 0.0001 or 0.001% v/v.{11598} Ocular administration of tafluprost (0.0005% v/v) reduces intraocular pressure in normotensive monkeys.{11598} Formulations containing tafluprost have been used in the treatment of open-angle glaucoma and ocular hypertension.

• Artikelnummer: CAY9002405-1
• Hersteller: Cayman Chemical
• Hersteller Artikelnummer: 9002405-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK
• Methode: GC-MS, LC-MS, Isotopenmarkierung